Platelet-specific antigens associated with the formation of alloantibodies in exposed patients are the basis for human platelet antigen (HPA) categorization. Over the years, these antigenic determinants have been mapped to a relatively short list of platelet-expressed adhesion/aggregation molecules, namely GPIa, GPIb, and GPIIb/IIIa.

Antigens

Table 31.1 lists current nomenclature for the various HPA groups with their associated other names, the major protein within which the antigenic epitope resides, and relative frequencies in the white population. HLA Class I and A/B/H group antigens are also found on the platelet surface. For the latest allelic frequency information, the Immuno Polymorphism Database section on HPA can be queried at http://www.ebi.ac.uk/ipd/hpa/ .

Table 31.1
Human Platelet Antigen Table
Modified from Metcalfe, P, Watkins, N. A, Ouwehand, W. H., Kaplan, C., Newman, P., Kekomaki, R., et al. (2003). Nomenclature of human platelet antigens. Vox Sang, 85 (3), 240–245; Allen et al., 2005; https://www.ebi.ac.uk/ipd/hpa/table1.html .
System Antigen Other Names Glycoprotein Antigen Frequency (%)
HPA-1 HPA-1a
HPA-1b
Zw a , Pl A1
Zw b , Pl A2
GPIIIa (CD61) 97.9
28.8
HPA-2 HPA-2a
HPA-2b
Ko b
Ko a , Sib a
GPIbα (CD42b) >99.9
13.2
HPA-3 HPA-3a
HPA-3b
Bak a , Lek a
Bak b
GPIIb (CD41) 80.95
69.8
HPA-4 HPA-4a
HPA-4b
Yuk b , Pen a
Yuk a , Pen b
GPIIIa (CD61) >99.9
<0.1
HPA-5 HPA-5a
HPA-5b
HPA-6bw
HPA-7bw
HPA-8bw
HPA-9bw
HPA-10bw
HPA-11bw
HPA-12bw
HPA-13bw
HPA-14bw
Br b , Zav b
Br a , Zav a , Hc a
Ca a , Tu a
Mo a
Sr a
Max a
La a
Gro a
ly a
Sit a
Oe a
GPIa (CD49b)

GPIIIa (CD61)
GPIIIa (CD61)
GPIIIa (CD61)
GPIIb (CD41)
GPIIIa (CD61)
GPIIIa (CD61)
GPIbβ (CD42c)
GPIa (CD49b)
GPIIIa (CD61)

99.0
19.7
0.7
0.2
<0.01
0.6
<1.6
<0.25
0.4
0.25
<0.17
HPA-15 HPA-15a
HPA-15b
HPA-16bw
HPA-17bw
HPA-18bw
HPA-19bw
HPA-20bw
HPA-21bw
HPA-22bw
HPA-23bw
HPA-24bw
HPA-25bw
HPA-26bw
HPA-27bw
HPA-28bw
HPA-29bw
Gov b
Gov a
Duv a
Va a
Cab a
Sta
Kno
Nos
Sey
Hug
Cab2 a+
Swi a
Sec a
Cab3 a+
War
Kha b
CD109 (CD109)

GPIIIa (CD61)
GPIIb/IIIa (CD61)
GPIa (CD49b)
GPIIIa (CD61)
GPIIb (CD41)
GPIIIa (CD61)
GPIIb (CD41)
GPIIIa (CD61)
GPIIb (CD41)
GPIa (CD49b)
GPIIIa (CD61)
GPIIb (CD41)
GPIIb (CD41)
GPIIIa (CD61)

74
81
<1
<0.4
Case report
Case report
Case report
Case report
Case report
Case report
Case report (<1)
Case report
Case report
Case report (<1)
Case report
Case report
Pl T
Vis
Pe a
Dy a
Mou a
Lap a
GPV
GPIV
GPIbα (CD42b)
38 kDa GP
Unknown
GPIIb (CD41)
>99.9

26

Mode of Inheritance

Of the 35 HPAs, 12 have been categorized into six biallelic groups (HPA-1, 2, 3, 4, 5, 15). Designated “a” antigen of the pair is typically the high-frequency antigen, whereas “b” antigen is the low-frequency antigen. The remaining 23 HPAs do not appear to correspond to a pair of alleles and are all designated as “b” antigens due to their low population frequency. It is hypothesized that due to the very low frequency of the “b” antigen that the probability of having a “bb” homozygote would be exceedingly rare and therefore no antibodies against a hypothetical corresponding “a” antigen have been clinically documented.

Molecular Basis of Type

The majority of HPAs reside on platelet-specific adhesion/aggregation molecules, which include GPIIb, GPIIIa, GPIa, GPIbα, GPIbβ, GPIV, GPV, and CD109. Originally, typing was performed with patient-derived antisera; however, an important limitation is that patients often have additional antibodies against Class I HLA antigens and therefore the sera was not monospecific and contaminated with anti-HLA antibodies. Once the molecular determinants for HPA type were discovered to be due to amino acid substitutions at specific points, the application of molecular methods to perform typing using DNA-based techniques became the “gold standard.”

Disease Associations

Alloantibody formation against HPA antigens is associated with several forms of thrombocytopenia, specifically neonatal alloimmune thrombocytopenia (NAIT), posttransfusion purpura (PTP), and platelet transfusion refractoriness (see Chapter 94, Chapter 69, Chapter 57 , respectively).

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here